Clinical trials: Hospitalized COVID-19
COVID-19, Coronavirus Infection
Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"
The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in controlling this disease in hospitalized patients…
- Conditions
- COVID-19, Coronavirus Infection, Virus Disease, Acute Respiratory Infection
- Trial name
- NCT04403100
- Testing
- Hydroxychloroquine Sulfate Tablets, Lopinavir/ Ritonavir Oral Tablet, Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets
- Where
- 4 sites in Brazil
- Volunteers
- 1,968 people
- Sponsor
- Cardresearch
Covid19, Hypoxemia
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
Patients with COVID-19 frequently develop lower respiratory complications. Difficulty breathing and a low concentration of oxygen in the blood are of concern in patients with COVID-19, as they indicate that the lungs may be…
- Trial name
- NCT04771000
- Testing
- Ambrisentan
- Where
- 13 sites in Croatia, Spain
- Volunteers
- 88 people
- Sponsor
- Noorik Biopharmaceuticals AG
COVID-19
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19
This study will compare two drugs (hydroxychloroquine and azithromycin) to see if hydroxychloroquine is better than azithromycin in treating hospitalized patients with suspected or confirmed COVID-19.
- Trial name
- HAHPS (NCT04329832)
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Intermountain Health Care, Inc.
COVID, SARS-CoV 2
Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est
Healthcare centers treated several hundreds of patients with Covid-19 and prospectively gathered information in electronic format between March, 2020 to April, 2020.
- Trial name
- NCT04366206
- Where
- 2 sites in France
- Volunteers
- 143 people
- Sponsor
- Centre Hospitalier Intercommunal Robert Ballanger
Problems Related to Life-Management Difficulty
Beyond COVID-19: Supporting Resilience With a Trauma-informed Music Composition Program
This study explores the feasibility and acceptability of a music composition intervention to support resilience in survivors of serious illness hospitalized during the COVID-19 pandemic.
- Trial name
- NCT05727514
- Testing
- music composition
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
COVID19
DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19)
The aim of the study is to compare a treatment with doxycycline vs a placebo as soon as the patient is confirmed COVID-19 + and before the onset of oxygen dependence with the aim of reducing or even abolishing the cytokine…
- Trial name
- DYNAMIC (NCT04371952)
- Testing
- Doxycycline
- Where
- 6 sites in France
- Sponsor
- Nantes University Hospital
Pneumonia, Severe Acute Respiratory Syndrome
Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19
This phase III trial compares low dose whole lung radiation therapy to best supportive care plus physicians choice in treating patients with COVID-19 infection.
- Conditions
- Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- RESCUE1-19 (NCT04433949)
- Testing
- Best Practice, Low Dose Radiation Therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Emory University
COVID-19, Acute Respiratory Failure
COVID Cohort Study
The novel SARS-CoV-2 virus has quickly spread worldwide, with substantial morbidity and mortality. There is very limited understanding of the short- and longer-term inflammatory/immunological and clinical course.
- Trial name
- NCT04393155
- Testing
- COVID-19+ observational
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Vermont
Obesity, COVID-19 Infection
Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection
Although SARS-CoV-2 (Severe Acute Respiratory Syndrome-associated coronavirus) due to COVID-19 evolves poorly towards ARDS (Acute Respiratory Distress Syndrome) and death, there is to date no validated drug available for severe…
- Trial name
- NIVISCO (NCT04413838)
- Testing
- NIVOLUMAB, Routine standard of care
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Covid-19
Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients
The primary objective of the study is to evaluate cardiac and pulmonary hemodynamic changes over time as predictor of disease progression and outcome in COVID-19 patients admitted to ICU.
- Trial name
- COVID-HO (NCT04371679)
- Testing
- No interventions planned
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Hasselt University
COVID-19 Patients
Independent Predictors on Clinical Outcomes in SARS-CoV2 Patients
The clinical spectrum of COVID-19 can be very heterogeneous: from mild flu-like symptoms, to the form with severe pulmonary impairment (dyspnoea, tachypnoea, PaO2 / FiO2 ratio below 300 at arterial blood gas sampling, pulmonary…
- Trial name
- outcomes (NCT05162534)
- Testing
- effect of COVID-19 exposure
- Where
- Italy
- Volunteers
- 1,800 people
- Sponsor
- University Hospital of Ferrara
COVID-19 Respiratory Infection
Dynamics of Markers of Infection and Inflammation in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients
Patients requiring admission to the hospital due to a moderate and severe COVID-19 infection may differ in their ability to respond to viral infection and to eliminate viral load.
- Trial name
- NCT04887623
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- University Hospital Hradec Kralove
Infections, Coronavirus
Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19
The purpose of this study is to demonstrate the superiority of Polyoxidonium®, lyophilizate for solution for injections and topical application, 6 mg over placebo in hospitalized patients with coronavirus disease (COVID-19).
- Trial name
- NCT04381377
- Testing
- azoximer bromide
- Where
- 14 sites in Russia, Slovakia
- Volunteers
- 394 people
- Sponsor
- NPO Petrovax
Covid19, Severe Acute Respiratory Syndrome
Ivermectin in Adults With Severe COVID-19.
Since the onset of the disease, more than 40.5 million people have been diagnosed with COVID-19 and nearly 1.2 million people have died (October 21, 2020).
- Trial name
- NCT04602507
- Testing
- Ivermectin
- Where
- Colombia
- Volunteers
- 75 people
- Sponsor
- CES University
COVID-19
MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780463
- Testing
- MP0420, Remdesivir
- Where
- 105 sites in United States, Denmark and 8 more
- Volunteers
- 485 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, ARDS
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19
COVID-19 patients who develop severe disease often develop acute respiratory distress syndrome (ARDS) as a result of a dysregulated immune response.
- Trial name
- NCT04401475
- Testing
- SOC plus 15mg/kg EB05 IV
- Where
- 20 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Edesa Biotech Inc.
COVID-19
Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)
Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per UCLA treating physicians versus current care per UCLA treating physicians alone (control arm).
- Trial name
- COLHEART-19 (NCT04355143)
- Testing
- Colchicine Tablets, Current care per UCLA treating physicians
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- University of California, Los Angeles
Covid19
Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients
The adaptive immune response, consisting of antiviral T and B cells, is critical for providing protection against viruses such as SARS-CoV-2, both during an active infection and later following a subsequent exposure.
- Trial name
- NCT04892797
- Testing
- Covid-19+ observational
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Vermont
Sarcopenia, Covid19
Sarco-COVID Study: Measuring the Loss of Skeletal Muscle Mass in the Hospitalized Patient With the Diagnosis of COVID-19
The COVID-19 pandemic is having a devastating global impact, and older adults who experience it are at higher risk of death from the disease.
- Trial name
- SARCO-COVID (NCT04780126)
- Testing
- Sarcopenia diagnosis
- Where
- Spain
- Volunteers
- 64 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
Covid19, SARS-CoV2 Infection
Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT
This randomized placebo-controlled double-blinded clinical trial aims to test the efficacy of administering atorvastatin 40 mg to hospitalized COVID-19 patients for 28 days on the all-cause 28-day mortality.
- Conditions
- Covid19, SARS-CoV2 Infection, COVID-19 Pneumonia
- Trial name
- COVID-STAT (NCT04952350)
- Testing
- Atorvastatin 40 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 220 people
- Sponsor
- Mansoura University